IL212984A - Vaccines to treat or reduce the risk of mammalian viral infection containing at least two differentiated optimized HIV-1 viral polypeptides and drugs containing them - Google Patents

Vaccines to treat or reduce the risk of mammalian viral infection containing at least two differentiated optimized HIV-1 viral polypeptides and drugs containing them

Info

Publication number
IL212984A
IL212984A IL212984A IL21298411A IL212984A IL 212984 A IL212984 A IL 212984A IL 212984 A IL212984 A IL 212984A IL 21298411 A IL21298411 A IL 21298411A IL 212984 A IL212984 A IL 212984A
Authority
IL
Israel
Prior art keywords
vaccines
medicaments
polypeptides
mammal
risk
Prior art date
Application number
IL212984A
Other languages
English (en)
Hebrew (he)
Other versions
IL212984A0 (en
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Los Alamos National Security Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc, Los Alamos National Security Llc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of IL212984A0 publication Critical patent/IL212984A0/en
Publication of IL212984A publication Critical patent/IL212984A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL212984A 2008-11-18 2011-05-18 Vaccines to treat or reduce the risk of mammalian viral infection containing at least two differentiated optimized HIV-1 viral polypeptides and drugs containing them IL212984A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11570308P 2008-11-18 2008-11-18
US15218409P 2009-02-12 2009-02-12
US24818809P 2009-10-02 2009-10-02
PCT/US2009/064999 WO2010059732A1 (en) 2008-11-18 2009-11-18 Antiviral vaccines with improved cellular immunogenicity

Publications (2)

Publication Number Publication Date
IL212984A0 IL212984A0 (en) 2011-07-31
IL212984A true IL212984A (en) 2016-12-29

Family

ID=42198483

Family Applications (2)

Application Number Title Priority Date Filing Date
IL212984A IL212984A (en) 2008-11-18 2011-05-18 Vaccines to treat or reduce the risk of mammalian viral infection containing at least two differentiated optimized HIV-1 viral polypeptides and drugs containing them
IL243991A IL243991B (en) 2008-11-18 2016-02-07 Antiviral vaccines with enhanced cellular immunogenicity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL243991A IL243991B (en) 2008-11-18 2016-02-07 Antiviral vaccines with enhanced cellular immunogenicity

Country Status (22)

Country Link
US (5) US9017691B2 (cg-RX-API-DMAC7.html)
EP (2) EP2358757B1 (cg-RX-API-DMAC7.html)
JP (4) JP5694945B2 (cg-RX-API-DMAC7.html)
CN (1) CN102282175B (cg-RX-API-DMAC7.html)
AP (1) AP3719A (cg-RX-API-DMAC7.html)
AU (1) AU2009316629B2 (cg-RX-API-DMAC7.html)
BR (2) BR122021004758B1 (cg-RX-API-DMAC7.html)
CY (1) CY1121215T1 (cg-RX-API-DMAC7.html)
DK (1) DK2358757T3 (cg-RX-API-DMAC7.html)
ES (1) ES2699685T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181776T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042397T2 (cg-RX-API-DMAC7.html)
IL (2) IL212984A (cg-RX-API-DMAC7.html)
LT (1) LT2358757T (cg-RX-API-DMAC7.html)
NZ (2) NZ593598A (cg-RX-API-DMAC7.html)
PL (1) PL2358757T3 (cg-RX-API-DMAC7.html)
PT (1) PT2358757T (cg-RX-API-DMAC7.html)
SG (1) SG10201408784SA (cg-RX-API-DMAC7.html)
SI (1) SI2358757T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800631T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010059732A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201104538B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3227814B2 (ja) 1992-07-29 2001-11-12 三菱マテリアル株式会社 スクラッププレス装置
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
SMT201800631T1 (it) 2008-11-18 2019-01-11 Beth Israel Deaconess Medical Ct Inc Vaccini antivirali con immunogenicità cellulare migliorata
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
ES3040856T3 (en) 2012-11-16 2025-11-05 Beth Israel Deaconess Medical Ct Inc Recombinant adenoviruses and use thereof
EP2983686B1 (en) 2013-01-07 2024-05-29 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
EP3666790A1 (en) 2013-10-04 2020-06-17 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
EP3054972B1 (en) * 2013-10-07 2019-02-27 The Trustees Of The University Of Pennsylvania Vaccines with interleukin-33 as an adjuvant
WO2015057950A1 (en) * 2013-10-16 2015-04-23 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
CA2941116A1 (en) * 2014-02-28 2015-09-03 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
EA202092521A1 (ru) 2014-09-26 2021-05-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
AU2015339463B2 (en) * 2014-10-27 2021-05-27 Academia Sinica Plant defense signaling peptides and applications thereof
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
JP2018528974A (ja) * 2015-09-25 2018-10-04 フロリダ大学 リサーチファウンデーション インコーポレイティッド ヒトおよびネコにおけるワクチンのためのｈｉｖ、ｓｉｖおよびｆｉｖの交差反応性ｔ細胞エピトープ
TWI792091B (zh) * 2015-12-15 2023-02-11 荷蘭商傑森疫苗防護公司 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法
KR102389489B1 (ko) 2016-06-16 2022-04-22 얀센 백신스 앤드 프리벤션 비.브이. Hiv 백신 제형
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2018050747A1 (en) 2016-09-15 2018-03-22 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
MY200554A (en) 2017-07-19 2024-01-03 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
EP3723771A4 (en) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
US11845788B2 (en) 2018-05-22 2023-12-19 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
AU2019345942A1 (en) 2018-09-25 2021-03-18 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
WO2020106713A1 (en) 2018-11-21 2020-05-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
IL297335A (en) * 2020-04-14 2022-12-01 Univ California Corona virus vaccine compounds
EP4149530A1 (en) 2020-05-12 2023-03-22 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
JP7693813B2 (ja) 2021-01-14 2025-06-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
MX2023009835A (es) 2021-02-23 2023-09-04 Janssen Vaccines & Prevention Bv Mutacion estabilizante de trimero de proteina de envoltura del vih.
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
EP4661878A2 (en) * 2023-02-07 2025-12-17 Merck Sharp & Dohme LLC Adjuvant formulations including low viscosity chitosan or chitosan derivatives

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20040101957A1 (en) * 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
EP1320621A4 (en) * 2000-09-15 2005-11-23 Merck & Co Inc IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02)
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
WO2003039470A2 (en) 2001-11-07 2003-05-15 Duke University Polyvalent immunogen of hiv
US20030219452A1 (en) 2001-11-27 2003-11-27 Haynes Barton F. HIV envelope V3-CCR5 binding site immunogen
KR101006594B1 (ko) 2002-04-25 2011-01-07 크루셀 홀란드 비.브이. 안정한 아데노바이러스 벡터 및 그 증식 방법
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
MX2007005256A (es) 2004-11-16 2008-03-11 Crucell Holland Bv Vacunas multivalentes que comprenden vectores virales recombinantes.
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
WO2007024941A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
CN101969997A (zh) 2007-03-27 2011-02-09 加利福尼亚大学董事会 急性传播的hiv包膜标记物
WO2010042817A1 (en) 2008-10-10 2010-04-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of hiv mosaic envelope proteins to optimize t-cell responses against hiv envelope
SMT201800631T1 (it) 2008-11-18 2019-01-11 Beth Israel Deaconess Medical Ct Inc Vaccini antivirali con immunogenicità cellulare migliorata
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
US9017961B2 (en) 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters

Also Published As

Publication number Publication date
SI2358757T1 (sl) 2018-12-31
JP6023233B2 (ja) 2016-11-09
WO2010059732A1 (en) 2010-05-27
JP5694945B2 (ja) 2015-04-01
CN102282175B (zh) 2015-09-30
BRPI0921588B1 (pt) 2021-12-28
US9017691B2 (en) 2015-04-28
CY1121215T1 (el) 2020-05-29
EP2358757B1 (en) 2018-09-12
ZA201204999B (en) 2014-08-27
PL2358757T3 (pl) 2019-02-28
US20170239344A1 (en) 2017-08-24
BRPI0921588A2 (pt) 2017-06-06
ZA201104538B (en) 2012-10-31
US20120076812A1 (en) 2012-03-29
PT2358757T (pt) 2018-12-04
JP6368416B2 (ja) 2018-08-01
HUE042397T2 (hu) 2019-06-28
LT2358757T (lt) 2018-11-26
NZ602504A (en) 2014-01-31
SG10201408784SA (en) 2015-02-27
US9670253B2 (en) 2017-06-06
BR122021004758B1 (pt) 2022-04-19
HK1164896A1 (en) 2012-09-28
US20190314492A1 (en) 2019-10-17
AU2009316629B2 (en) 2016-02-04
AP3719A (en) 2016-06-30
IL212984A0 (en) 2011-07-31
JP6224197B2 (ja) 2017-11-01
SMT201800631T1 (it) 2019-01-11
EP2358757A1 (en) 2011-08-24
IL243991A0 (en) 2016-04-21
US11331386B2 (en) 2022-05-17
US10426831B2 (en) 2019-10-01
US20160024156A1 (en) 2016-01-28
EP2358757A4 (en) 2013-07-31
HRP20181776T1 (hr) 2019-02-08
US20200397890A1 (en) 2020-12-24
CN102282175A (zh) 2011-12-14
AP2011005767A0 (en) 2011-06-30
ES2699685T3 (es) 2019-02-12
JP2018035177A (ja) 2018-03-08
NZ593598A (en) 2013-02-22
US10772952B2 (en) 2020-09-15
EP3470437A1 (en) 2019-04-17
AU2009316629A1 (en) 2011-07-07
JP2017052762A (ja) 2017-03-16
JP2012509340A (ja) 2012-04-19
DK2358757T3 (da) 2019-01-02
IL243991B (en) 2019-12-31
JP2015134775A (ja) 2015-07-27

Similar Documents

Publication Publication Date Title
IL212984A (en) Vaccines to treat or reduce the risk of mammalian viral infection containing at least two differentiated optimized HIV-1 viral polypeptides and drugs containing them
HUS2400017I1 (hu) Dolutegravir és lamivudin kombinációi HIV-fertõzés kezelésére
IL216605A (en) A pharmaceutical composition comprising 2-aryl-benzothiazole or 2-aryl-pyrido (d) thiazole, and its use in the preparation of a drug for the treatment of viral inflammation
IL188766A0 (en) Methods for reducing viral load in hiv-1 infected patients
IL213861A0 (en) Cyclosporine derivative for use in the treatment of hcv and hiv infection
AP3069A (en) Thienopyridine derivatives for the treatment and prvention of dengue virus infection
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
ZA201001585B (en) Spiropyrrolidines and their use against hcv and hiv infection
IL219945A (en) 1-GLP history with dual transduction and use of it to prepare a drug for the treatment of diabetes
ZA201103512B (en) Gaming system having viral assests and achievements
ZA200806310B (en) Viral hepatitis treatment
IL195683A0 (en) Recombinant viral vaccine
ZA200809488B (en) CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
PT2217230T (pt) Prevenção e tratamento de infeções secundárias após infeção viral
ZA201303610B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
IL224545A (en) Combined Pharmaceuticals for the Treatment and Prevention of Infectious Diseases
PL2694087T3 (pl) Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby
BRPI0814363A2 (pt) Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
IL219976A0 (en) Imp-3 oligopeptides and vaccines including the same
IL215228A (en) Use of isolated placental intermediate killing cells for vehicle production to treat viral infection
TWI370736B (en) Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus
IL198704A (en) Pharmaceuticals and vaccines to treat cancer or infection
IL225861A (en) Indazole-3-carboxamide derivatives and their use in the preparation of c-viral hepatitis drugs

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed